TYRP1 FiCAR T / Orion Corp - LARVOL DELTA

A novel SIRPA based FiCAR T cells therapy targeting TYRP1 to treat melanoma patients (AACR 2025) - "A well-known anti-TYRP1 binder flanvotumab's scfv was inserted into FiCAR-structure containing CD28 and CD3zeta intra cellular signaling domain and those CAR T cells were studied for both in vitro and in vivo function. TYRP1 based FiCAR grew normally and good transduction rates with low vector copy numbers were achieved. In addition, upon co-culture of TYRP1 FiCAR T cells with tumor cells expressing TYRP1 a rapid and significant release of pro-inflammatory cytokines was detected."

CAR T-Cell Therapy • Clinical • IO biomarker • Tumor mutational burden • Hematological Malignancies • Melanoma • Oncology • Solid Tumor • SIRPA • TMB • TYRP1